RecruitingNot ApplicableNCT05945342

Development and Application of Comprehensive Intervention Techniques for Adolescent Depression

Research and Application of Key Technologies for Early Identification, Risk Warning and Comprehensive Intervention of Adolescent Depression


Sponsor

First Affiliated Hospital of Zhejiang University

Enrollment

100 participants

Start Date

Jan 31, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

In order to realize the early identification, risk warning and comprehensive intervention of adolescent depression, this project carried out research on the diagnosis platform of adolescent depression, the construction of suicide risk warning and evaluation system, the development of interpersonal psychotherapy technology (IPT-A), and the rapid intervention technology of robotic navigation repetitive transcranial magnetic stimulation (rTMS). Through the extraction of psychological, peripheral and central biological characteristics of adolescent depression and the establishment of a diagnostic platform, combined with artificial neural network to achieve efficient and accurate identification of high risk of suicide population. Antidepressant drugs combined with psychotherapy and antidepressant drugs combined with rTMS physical therapy were used to improve the clinical effective rate and recovery rate. Finally, a comprehensive prevention and control technology suitable for hospitals, schools and families to participate in.


Eligibility

Min Age: 12 YearsMax Age: 18 Years

Inclusion Criteria6

  • Sign a written informed consent to participate in the trial and receive treatment;
  • Meet the diagnostic criteria of depression in DSM-5, and have no psychotic characteristics;
  • Child Depression Rating Scale-Revised (CRs-R)≥40 points;
  • Hamilton Depression Scale (HAMD-24) scores ≥20;
  • First or recurrent depressive episode, not received antidepressant drugs and systematic psychotherapy in recent 2 months;
  • The Han nationality, right hand

Exclusion Criteria6

  • Have other mental disorders, or have a history of other mental disorders, such as attention deficit movement disorder, autism, and developmental retardation;
  • Patients with current infections, trauma, autoimmune diseases, other unstable medical conditions, or who are receiving hormone therapy;
  • Patients with a history of craniocerebral injury and coma;
  • A family history of bipolar disorder, seizures, or epilepsy;
  • Those who had substance abuse or dependence within the first three months of enrollment;
  • Patients with contraindications for MRI examination such as metal foreign body in the skull or abnormal brain structure found in MRI examination.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHEREscitalopram combined with rTMS

The subjects received Robotic navigational repetitive transcranial magnetic stimulation while taking medication

DRUGEscitalopram combined with sham rTMS

The subjects received sham Robotic navigational repetitive transcranial magnetic stimulation while taking medication

DRUGEscitalopram

The US Food and Drug Administration(FDA) has only approved fluoxetine and escitalopram for the treatment of adolescent depression

OTHERInterpersonal Psychotherapy for Adolescent

Interpersonal Psychotherapy for Adolescent(IPT-A), A modified version of interpersonal psychotherapy, is shorter than the standard therapy duration (12-16 sessions), with a total of eight sessions, retaining the structure of the standard IPT but employing a series of strategies to extract the most important components to speed up the time process.

OTHEREscitalopram combined with psychotherapy

The subjects received adolescent interpersonal psychotherapy for adolescent(IPT-A) while taking medication


Locations(1)

The First Affiliated Hospital of Zhejiang University

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05945342


Related Trials